secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2023-02-15T23:59:59+00:00
Accession:  0001193125-23-040254
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IO Biotech launches $19.5M ATM equity program with Cowen, up to $75M total
--------------------------------------------------------------------------

- Filed prospectus supplement for at-the-market offering of common stock up to $19.5 million.
- Sales agreement with Cowen and Company allows additional sales up to $75 million aggregate.
- Proceeds to fund preclinical studies, clinical trials, product acquisitions, and working capital.
- Cowen receives 3% commission on gross sales; shares sold through Nasdaq or other markets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523040254/0001193125-23-040254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312523040254/d264518d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-040254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer